|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0151 - 0.0151|
|52 Week Range||0.0151 - 0.0151|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, November 02, 2023--MindMed today reported its financial results for the quarter ended September 30, 2023.
NEW YORK, October 26, 2023--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.
NEW YORK, October 24, 2023--Enrollment completed for MMED007, the Phase 2a study evaluating repeated low-dose administration of MM-120 for the treatment of adults with ADHD.